Community Health Systems, Inc.

DB:CG5 Stock Report

Market Cap: €431.7m

Community Health Systems Valuation

Is CG5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CG5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CG5's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CG5's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CG5?

Key metric: As CG5 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CG5. This is calculated by dividing CG5's market cap by their current revenue.
What is CG5's PS Ratio?
PS Ratio0.04x
SalesUS$12.55b
Market CapUS$447.49m

Price to Sales Ratio vs Peers

How does CG5's PS Ratio compare to its peers?

The above table shows the PS ratio for CG5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
M12 M1 Kliniken
0.8x7.8%€272.8m
RHK RHÖN-KLINIKUM
0.5x2.1%€977.3m
MED MEDICLIN
0.2x0.7%€140.6m
LIK LIMES Schlosskliniken
2.5x16.5%€102.6m
CG5 Community Health Systems
0.04x2.0%€447.5m

Price-To-Sales vs Peers: CG5 is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does CG5's PS Ratio compare vs other companies in the DE Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.0.6x4.0%
CG5 Community Health Systems
 0.04x2.0%US$447.49m
EIF MedNation
0.08xn/aUS$4.00m
TLIK Arzneiwerk VIDA
0.05xn/aUS$3.26m
No more companies available in this PS range
CG5 0.0xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
Industry Avg.0.6x22.5%
CG5 Community Health Systems
 0.04x97.6%US$447.49m
No more companies

Price-To-Sales vs Industry: CG5 is good value based on its Price-To-Sales Ratio (0x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is CG5's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CG5 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.04x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: CG5 is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CG5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.22
€4.27
+32.6%
23.6%€5.72€2.38n/a7
Feb ’26€3.10
€4.27
+37.7%
23.6%€5.72€2.38n/a7
Jan ’26€2.84
€4.66
+64.3%
22.1%€5.71€2.38n/a7
Dec ’25€3.24
€4.67
+44.1%
22.1%€5.72€2.38n/a7
Nov ’25€3.70
€4.87
+31.6%
9.0%€5.56€4.45n/a7
Oct ’25€5.55
€4.74
-14.6%
17.9%€5.47€2.73n/a8
Sep ’25€4.94
€4.74
-4.1%
17.9%€5.47€2.73n/a8
Aug ’25€4.82
€4.76
-1.2%
18.4%€5.55€2.78n/a8
Jul ’25€3.10
€4.07
+31.3%
24.4%€5.52€2.76n/a8
Jun ’25€3.54
€4.07
+14.9%
24.4%€5.52€2.76n/a8
May ’25€3.06
€4.11
+34.2%
25.0%€5.61€2.80n/a8
Apr ’25€3.10
€4.07
+31.3%
28.3%€5.53€2.76n/a8
Mar ’25€2.54
€4.27
+68.1%
26.1%€5.54€2.86n/a7
Feb ’25€3.38
€4.55
+34.6%
27.0%€5.94€2.83€3.107
Jan ’25€2.88
€4.35
+50.9%
35.6%€6.02€2.32€2.847
Dec ’24€2.34
€4.27
+82.6%
35.6%€5.92€2.28€3.247
Nov ’24€1.98
€4.54
+129.4%
32.6%€6.12€2.35€3.707
Oct ’24€2.58
€6.20
+140.3%
43.6%€12.87€3.74€5.558
Sep ’24€3.08
€6.20
+101.3%
39.2%€12.49€3.63€4.949
Aug ’24€3.98
€6.20
+55.7%
39.9%€12.59€3.66€4.829
Jul ’24€3.88
€6.20
+59.7%
39.9%€12.59€3.66€3.109
Jun ’24€3.04
€6.23
+105.0%
40.8%€12.77€3.71€3.549
May ’24€5.35
€7.97
+49.0%
27.0%€12.48€5.45€3.068
Apr ’24€4.40
€8.15
+85.2%
23.9%€12.68€6.00€3.109
Mar ’24€5.70
€7.78
+36.5%
32.2%€12.97€2.83€2.5410
Feb ’24€4.76
€5.11
+7.3%
53.3%€12.64€2.76€3.3810
Analyst Price Target
Consensus Narrative from 7 Analysts
€4.18
Fair Value
23.0% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 11:02
End of Day Share Price 2025/02/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Community Health Systems, Inc. is covered by 34 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Benjamin MayoBaird
Andrew MokBarclays